The FDA halted the use of Regeneron’s REGEN-COV and Eli Lilly’s Bamlanivimab and etesevimab COVID-19 antibody drugs.   Emergency authorization for the monoclonal antibody treatments was revoked by the U.S. FDA citing the drugs were less able to target the Omicron variant because of mutations.     Last month, the U.S. government paused the distribution of Regeneron and Lilly’s treatments until pending new data on their efficacy against Omicron.   According to the FDA, reauthorization ...